Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases

S Hummel, H Van Aken, A Zarbock - Current opinion in …, 2014 - journals.lww.com
S Hummel, H Van Aken, A Zarbock
Current opinion in hematology, 2014journals.lww.com
Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in
inflammatory diseases. Several promising CXCR4 antagonists are in different stages of
development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for
short-term application.
Summary
Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in inflammatory diseases. Several promising CXCR4 antagonists are in different stages of development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for short-term application.
Lippincott Williams & Wilkins